| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma WEST HAVEN, C.T. and EMERYVILLE, C.A. -- April 18, 2006 -- Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. announced today that Nexavar® (sorafenib) tablets has been granted orphan medicinal product status for the treatment of hepatocellular carcinoma (HCC), or liver cancer, by the European Commission. This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA). "This orphan medicinal product designation demonstrates the European Commission's commitment to the study and development of treatments for rare diseases," said Susan Kelley, M.D., vice president, Oncology, Bayer Pharmaceuticals Corporation. "This support adds momentum to our research efforts with Nexavar and brings hope of a new treatment option to liver cancer patients in Europe."
SOURCE: Bayer Pharmaceuticals Corporation
|